+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Analyses from the JPAD, POPADAD and AAA trials



Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Analyses from the JPAD, POPADAD and AAA trials



Thrombosis and Haemostasis 104(6): 1085-1088




(PDF emailed within 0-6 h: $19.90)

Accession: 051647857

Download citation: RISBibTeXText

PMID: 20941462

DOI: 10.1160/TH10-05-0333


Related references

Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 301(18): 1909-1919, 2009

Aspirin for the Prevention of Cardiovascular Events in Patients With Peripheral Artery Disease: A Meta-analysis of Randomized Trials. Yearbook of Anesthesiology and Pain Management 2010: 9-11, 2010

Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 8(): 21-21, 2007

Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease. Praxis 98(22): 1315-1316, 2009

Aspirin for prevention of stroke and cardiovascular events among patients with peripheral artery disease. JAMA 302(11): 1165; Author Reply 1165-6, 2009

Differential Effect of Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Diabetes Management: A subanalysis of the JPAD trial. Yearbook of Vascular Surgery 2012: 36-37, 2012

Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: a subanalysis of the JPAD trial. Diabetes Care 34(6): 1277-1283, 2011

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial. Circulation 135(7): 659-670, 2016

The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. Yearbook of Vascular Surgery 2009: 8-9, 2009

The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. Bmj 337: A1840, 2008

Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. Bmj 339: B4531, 2009

Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. Diabetic Medicine 34(3): 316-327, 2016

Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus. Clinical Cardiology 35(12): 722-729, 2013

Aspirin for primary prevention of cardiovascular disease events in diabetes: the balancing act?. Journal of the Royal College of Physicians of Edinburgh 48(4): 332-333, 2018

Primary Prevention of Cardiovascular Events With Aspirin in Patients With Diabetes. Diabetes Spectrum 24(1): 47-49, 2011